What do systematic reviews say?

Primary (complete) wound closure vs Secondary (partial) wound closure

Primary (complete) wound closure showed no clear difference in maximum mouth opening (mean) compared with secondary (partial) wound closure; GRADE not reported.

• Surgical techniques for the removal of mandibular wisdom teeth 2020 · Cochrane All outcomes

  7 days
  MD -0.29 [-0.90, 0.32]
  4 studies · 274 participants
  GRADE not reported

Triangular flap vs Envelope flap

Triangular flap led to lower maximum mouth opening compared with envelope flap; GRADE not reported.

• Surgical techniques for the removal of mandibular wisdom teeth 2020 · Cochrane All outcomes

  7 days · short triangular vs envelope
  SMD -0.67 [-1.04, -0.30]
  2 studies · 158 participants
  GRADE not reported

Piezoelectric bone removal vs Conventional rotary handpiece

Piezoelectric bone removal led to higher trismus / maximum mouth opening (mean) compared with conventional rotary handpiece; GRADE not reported.

• Surgical techniques for the removal of mandibular wisdom teeth 2020 · Cochrane All outcomes

  7 days · piezoelectric vs conventional
  MD 2.68 [0.54, 4.81]
  4 studies · 110 participants
  GRADE not reported

Coronectomy vs Complete extraction (odontectomy)

Coronectomy showed no clear difference in maximum mouth opening (mean) compared with complete extraction (odontectomy); GRADE not reported.

• Surgical techniques for the removal of mandibular wisdom teeth 2020 · Cochrane All outcomes

  7 days
  MD -2.94 [-8.20, 2.32]
  1 study · 30 participants
  GRADE not reported

Alteplase vs urokinase

Alteplase showed no clear difference in referral for thoracic surgery (open or thorascopic) compared with urokinase (low certainty).

• Intra‐pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult… 2019 · Cochrane Headline outcomes only
  OR 0.46 [0.04, 5.24]
  1 study · 99 participants
  Low

Streptokinase vs urokinase

Streptokinase showed no clear difference in referral for thoracic surgery (open or thorascopic) compared with urokinase (low certainty).

• Intra‐pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult… 2019 · Cochrane Headline outcomes only
  OR 1 [0.13, 7.72]
  1 study · 50 participants
  Low

Bispectral index vs clinical signs

• Bispectral index for improving intraoperative awareness and early postoperative recovery in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  22 studies · 1494 participants
  Low

Bispectral index vs ETAG

The review found no eligible studies for this question.

• Bispectral index for improving intraoperative awareness and early postoperative recovery in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): secondary outcomes

Target of rapamycin inhibitors (TOR‐I) may leads to higher thrombocytopenia compared with calcineurin inhibitors (CNI): secondary outcomes (low certainty).

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  RR 5.26 [2.87, 9.63]
  4 studies · 593 participants
  Low

Target of rapamycin inhibitors (TOR‐I) vs antimetabolites: secondary outcomes

Target of rapamycin inhibitors (TOR‐I) may leads to lower leucopenia compared with antimetabolites: secondary outcomes (low certainty).

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  RR 0.43 [0.33, 0.56]
  15 studies · 8396 participants
  Low

Target of rapamycin inhibitors (TOR‐I) vs antimetabolites: secondary outcomes

Target of rapamycin inhibitors (TOR‐I) may leads to higher thrombocytopenia compared with antimetabolites: secondary outcomes (low certainty).

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  RR 1.96 [1.38, 2.79]
  8 studies · 5028 participants
  Low

Intervention not reported

The intervention showed no clear difference in leucopenia (moderate certainty).

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  RR 0.99 [0.7, 1.4]
  5 studies · 1012 participants
  Moderate

Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes

Low may leads to lower thrombocytopenia compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (low certainty).

• Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
  RR 0.58 [0.44, 0.75]
  9 studies · 2242 participants
  Low

Intervention not reported

The intervention probably leads to lower all VTE (subgroup analysis open only) (moderate certainty).

• Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery 2019 · Cochrane Headline outcomes only
  OR 0.42 [0.29, 0.6]
  6 studies · 1503 participants
  Moderate

Intervention not reported

The intervention probably leads to lower all DVT (subgroup analysis open only) (moderate certainty).

• Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery 2019 · Cochrane Headline outcomes only
  OR 0.43 [0.3, 0.62]
  6 studies · 1503 participants
  Moderate

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Taxane‐containing chemotherapy showed no clear difference in febrile neutropenia compared with any chemotherapy without taxane (moderate certainty).

• Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
  OR 1.43 [0.89, 2.31]
  23 studies · 34154 participants
  Moderate

TACE followed by 3‐DCRT vs chemoembolisation

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: leukopenia compared with TACE (very low certainty).

• Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
  RR 1.12 [0.92, 1.34]
  5 studies · 438 participants
  Very low

TNF‐α blockers intervention vs placebo or additional treatment

The review found no eligible studies for this question.

• TNF‐α blockers for the treatment of Kawasaki disease in children 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines leads to lower adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (high certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 0.62 [0.4, 0.97]
  4 studies · 279 participants
  High

Taxane followed by anthracyclines vs anthracyclines followed by taxane

Taxane followed by anthracyclines showed no clear difference in adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (moderate certainty).

• Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer 2019 · Cochrane Headline outcomes only
  RR 1.25 [0.86, 1.82]
  1 study · 280 participants
  Moderate